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OBJECTIVES We investigated whether the insertion/deletion (I/D) polymorphism in the angiotensin-
converting enzyme (ACE) gene modulates vasomotor tone and endothelial function.
BACKGROUND The deletion allele of the ACE I/D polymorphism has been associated with increased
incidence of cardiovascular pathology. The risk is synergistically increased in patients who also
possess the C allele at position 1,166 of the angiotensin type I (AT1) receptor gene.
METHODS In 177 patients with coronary atherosclerosis or its risk factors, we investigated endothelial
function with intracoronary acetylcholine (ACH), endothelium-independent smooth muscle
function with sodium nitroprusside (SNP) and basal nitric oxide activity with L-NG
monomethyl arginine.
RESULTS Compared with ACE II genotype, patients with the ACE DD genotype had lower coronary
microvascular and epicardial responses with SNP (coronary blood flow increase 196 6 26%
vs. 121 6 11%, p 5 0.003, and diameter increase 21.9 6 2% vs. 17 6 1%, p 5 0.03, ACE
II vs. DD, respectively). L-NG monomethyl arginine induced greater constriction in patients
with the ACE DD compared with ACE II genotype (coronary blood flow 210 6 4% vs.
11 6 5%, p 5 0.003, ACE DD vs. II and diameter constriction 26.3 6 1.2% vs. 21.9 6
1.2%, p 5 0.01, respectively, in patients with atherosclerosis). No difference in ACH-
mediated vasomotion was detected between the three ACE genotypes. The AT1 receptor
polymorphism did not influence responses to either SNP or ACH.
CONCLUSIONS Patients possessing the D allele of the ACE gene have increased vascular smooth muscle tone.
The enhanced tone appears to be counterbalanced by an increase in basal nitric oxide activity
in patients with atherosclerosis. (J Am Coll Cardiol 2000;36:1579–86) © 2000 by the
American College of Cardiology
The insertion/deletion (I/D) polymorphism of the
angiotensin-converting enzyme (ACE) gene has recently
been identified as a possible risk factor for several cardio-
vascular disorders. The gene is located on chromosome 17,
and the polymorphism is characterized by the presence
(insertion [I]) or absence (deletion [D]) of a 287-base-pair
alu repeat within intron 16. Because the polymorphism is
located in an intron, it is believed to be a neutral marker in
strong linkage disequilibrium with one or more unknown
functional variants located in or close to the ACE gene
(1,2). The three genotypes include ACE DD and II
homozygotes and ID heterozygotes (3). Cambien and
colleagues (4) were the first to report an increased frequency
of the ACE D allele in patients with myocardial infarction
(MI). They also observed a synergistic effect between the
ACE D allele and the C allele of an adenine/cytosine (A/C)
base substitution at position 1,166 of the angiotensin type I
(AT1) receptor gene. The risk of MI appeared to be greatest
in individuals with the ACE DD and AT1 receptor CC
genotypes (5). Synergism between the ACE gene polymor-
phism and conventional risk factors such as smoking and
hyperlipidemia has also been observed (6,7). Though some
studies have noted the absence of an association (8–10), a
recent meta-analysis confirmed that the presence of the
ACE D allele was a risk factor for MI (11). Despite
considerable interest in this genetic variant, few studies have
explored the potential vascular mechanisms by which pres-
ence of the ACE D allele leads to these deleterious effects.
Abnormal epicardial coronary vasoconstriction and de-
pressed microvascular dilation are early features of athero-
sclerosis (12,13). This results from endothelial cell dysfunc-
tion, which modulates smooth muscle function and
contributes to the pathogenesis of MI and ischemia.
Angiotensin-converting enzyme, a key component of the
circulating and vascular renin-angiotensin systems promotes
the synthesis of angiotensin II, an important regulator of
vascular function (14). By stimulating the AT1 receptor,
angiotensin II promotes vasoconstriction, both directly and
through endothelin release or augmentation of sympathetic
tone. Moreover, increased free radical generation by angio-
tensin II may also contribute to endothelial dysfunction
(15–18). In addition, ACE also metabolizes locally synthe-
sized bradykinin, which would promote vasoconstriction by
reducing bradykinin-dependent nitric oxide (NO) release.
This vasoconstriction is partly inhibited by angiotensin
II–mediated release of NO from the endothelium (19–22).
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Because individuals with the ACE D allele have higher
plasma and tissue ACE levels, we hypothesized that the D
allele of the ACE gene, by increasing local angiotensin II
generation and decreasing bradykinin activity, may modu-
late coronary vascular tone (23–27).
Thus, the aims of our study were to investigate whether
the presence of the ACE D allele was: a) associated with
increased smooth muscle constrictor tone tested with so-
dium nitroprusside (SNP), b) a determinant of basal NO
activity assessed by the response to L-NG monomethyl
arginine (L-NMMA) and c) a risk factor for endothelial
dysfunction, as tested with acetylcholine (ACH), in both
coronary conductance and resistance vessels. In view of the
previous report that the ACE polymorphism was not a
determinant of vasomotor function in normal subjects, we
conducted this study in patients with one or more risk
factors for atherosclerosis in whom there is evidence of
increased tissue ACE activity (6,7,28). We also evaluated
whether any association between the ACE gene polymor-
phism and vascular phenotype was modulated by the AT1
receptor A/C gene polymorphism.
METHODS
Study population. We studied patients undergoing diag-
nostic cardiac catheterization for investigation of chest pain
or abnormal noninvasive tests. Risk factors were defined as
the presence of hypertension (blood pressure . 140/90),
hypercholesterolemia (low-density lipoprotein choles-
terol . 160 mg/dL), diabetes, current smoking or smoking
in the previous year and age .65 years. Patients with
coronary artery disease (CAD) who either had atheroscle-
rotic plaques or more severe stenoses in one or more of their
coronary arteries were included in the group with athero-
sclerosis. Patients with recent MI, valvular heart disease or
those treated with ACE inhibitors in the previous two
weeks were excluded. All cardiac medications were with-
drawn at least 48 h before the study, and aspirin or other
cyclooxygenese inhibitors were discontinued seven days
before. The study was approved by the National Heart,
Lung, and Blood Institute Investigational Review Board,
and informed consent was obtained from all patients.
Protocol. After diagnostic coronary angiography was per-
formed, a 6F guide catheter was introduced into the
proximal segment of a coronary artery, and blood flow
velocity was measured using a 0.018 inch wire equipped
with a Doppler crystal at its tip (Cardiometrics Flowire,
Cardiometrics, Endosonics Corp., Rancho Cordova, Cali-
fornia). The Doppler flow wire was advanced into either the
left main or the proximal segment of a major epicardial
artery. The wire tip was carefully positioned in a segment of
the vessel that was straight and free of any major branches
1 cm from the tip, that produced a characteristic and stable
flow velocity signal, and that could be imaged without
overlap from other vessels, thus allowing for quantitative
measurements of the coronary artery diameter. Flow mea-
surements were made in a coronary artery with ,30%
stenosis to ensure that microvascular function could be
measured. All drugs were infused directly into the left main
or the right coronary artery via the guide catheter at rates
ranging between 1 and 2 ml/min. The dose of drugs
administered was halved in the right coronary artery.
Study 1. In 177 patients (92 with coronary atherosclerosis
and 85 with angiographically normal coronary arteries and
risk factors for atherosclerosis) we evaluated the relationship
between both the ACE and AT1 receptor gene polymor-
phisms and the coronary vasomotor responses to ACH and
SNP. After a 5-min infusion of dextrose 5% at 1 ml/min,
measurement of coronary blood flow velocity and coronary
angiography were performed and repeated after each inter-
vention (13). Endothelium-dependent vasodilation was es-
timated by measuring coronary flow and epicardial re-
sponses to an infusion of intracoronary ACH at an
estimated intracoronary concentration of 1026 (mol/L).
Ten minutes after performing the ACH measurements and
repeat baseline measurements, endothelium-independent
coronary smooth muscle function was estimated with intra-
coronary SNP given at 40 mg/min for 3 min.
Study 2. In a subgroup of 76 patients (38 with coronary
atherosclerosis and 38 with normal coronary arteries with
risk factors for atherosclerosis) we evaluated the relationship
between the ACE I/D polymorphism and basal NO pro-
duction. Baseline measurements were made after a 10-min
infusion of dextrose 5%. This was followed by a 10-min
infusion of L-NMMA (Clinalfa AG, Switzerland), a spe-
cific inhibitor of NO synthesis from L-arginine, at 64
mmol/min (1 ml/min).
Measurement of coronary blood flow and diameter.
Coronary blood flow was derived from the coronary blood
flow velocity and diameter measurements using the formula
(pi 3 average peak velocity 3 0.125 3 diameter2) (13).
Coronary vascular resistance was calculated as mean arterial
pressure divided by coronary blood flow. For calculating
flow, coronary artery diameter was measured in a 0.5 cm
segment of vessel beginning 0.25 cm beyond the tip of the
flow wire. Coronary angiograms were recorded using a
cineangiographic system (Toshiba, Inc., Tustin, California),
and quantitative angiography was performed with the
Abbreviations and Acronyms
A/C 5 adenine/cytosine
ACE 5 angiotensin-converting enzyme
ACH 5 acetylcholine
ANOVA 5 analysis of variance
AT1 5 angiotensin type I
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D 5 deletion
I 5 insertion
L-NMMA 5 L-NG monomethyl arginine
MI 5 myocardial infarction
NO 5 nitric oxide
PCR 5 polymerase chain reaction
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ARTREK software (Quantim 2001, Statview, Image-
Comm Systems, Inc., Mountainview, California).
In addition to the measurement of the diameter at the
level of the Doppler flow wire, 0.5 cm segments of mid and
distal regions of the epicardial coronary arteries were also
measured by quantitative coronary angiography.
Determination of ACE and AT1 receptor genotypes.
Genotyping was performed by laboratory personnel who
had no knowledge of the vascular function data.
Angiotensin-converting enzyme genotypes were determined
by use of the polymerase chain reaction (PCR) according to
previously published protocols (1). In brief, a set of primers
was designed to encompass the polymorphic region in
intron 16 of the ACE gene (sense primer 59 CTG-
GAGACCACTCCCATCCTTTCT 39 and antisense
primer 59 GATGTGGCCATCACATTCGTCAGAT
39). DNA was amplified for 35 cycles, each cycle composed
of denaturation at 94°C for 30 s, annealing at 58°C for 30 s,
and extension at 72°C for 30 s. The products were separated
by electrophoresis on 2% agarose gel and identified by
ethidium bromide staining. In order to verify the ACE DD
allele, each sample found to be ACE DD was reamplified
with the primers hace5a and hace5c, which recognize the
inserted sequence as previously described (9). This amplifi-
cation detected the presence of the I allele and produced no
product from the DNA with ACE DD genotype.
The genotyping of the AT1 1,166 A/C polymorphism
was accomplished by PCR amplification of a 282 bp
fragment encompassing the site using a forward primer: 59
GTAAGCTCATCCACCAAGAAGCCT 39 and a re-
verse primer: 59AGAAGCTCGTCGGCAGTAGACAG
39. The A to C transversion creates a Dde 1 restriction
enzyme site that, upon digestion, yields two fragments of
148 and 134 bps. The PCR amplification protocol was as
above, but the digested products were resolved on a 10%
acrylamide gel.
Statistical analysis. Data are expressed as mean 6 SEM.
Differences between means were compared by paired or
unpaired Student t test, as appropriate. All p values were
two-tailed, and a value ,0.05 was considered to indicate
statistical significance. Univariate comparisons between the
responses in patients with the ACE DD, ID and II
genotypes and AT1 AA, AC and CC genotypes were
performed using analysis of variance (ANOVA). To identify
the most parsimonious multivariate model for predicting
changes in coronary blood flow for each of SNP, ACH and
L-NMMA, we used the SAS Stepwise Procedure (stepwise
technique) on the regressors age, hypertension, diabetes,
cigarette use, total cholesterol level, high-density lipoprotein
level, presence of coronary atherosclerosis and the ACE
gene polymorphism (DD, ID or II). The significance level
for covariate entry and staying in the model was 0.15. The
three genotypes were defined with two dummy variables, as
opposed to defining them as one variable with three differ-
ent levels, to avoid the assumption of a linear relationship
between genotypes and the response. The GLM Procedure
of SAS was then applied to the final model to facilitate a
global test for the equality of the three genotype effects as
well as Bonferroni pairwise comparisons of the three geno-
types where significance was noted on the global test.
RESULTS
Study 1. The frequencies of the ACE D and I alleles were
57% and 43%, respectively, and the AT1 receptor A and C
alleles were 77% and 23%, respectively. These frequencies
were similar to those reported in previous studies (4,5,28),
and the genotype frequency did not deviate significantly
from that predicted by the Hardy–Weinberg equilibrium.
There were 102 (58%) men; mean age was 55 6 1 years; 67
(38%) were hypertensive; 106 (60%) were current or previ-
ous smokers; 29 (16%) had diabetes; and the mean choles-
terol level was 221 6 3 mg/dL. As reported previously,
ACE levels were significantly higher in patients with the D
allele (23). The distribution of conventional risk factors for
atherosclerosis and endothelial dysfunction was similar be-
tween the three groups of patients (Table 1).
Genotype and coronary vascular response to SNP. Base-
line systemic blood pressure, coronary epicardial diameter
and vascular resistance were similar in patients with all three
ACE and AT1 receptor genotypes (Table 2). Sodium
nitroprusside infusion reduced mean arterial pressure from
Table 1. Patient Characteristics for Each Genotype
Study 1 DD ID II
Number of patients 59 84 34
ACE level (U/L) 13.4 6 0.6 10.2 6 0.7 7.0 6 0.7*
Age (mean 6 SD) 55 6 1.3 55 6 1.3 58 6 1.7
Positive Hx of smoking (%) 38 (64) 50 (60) 17 (50)
Total cholesterol (mg/dL) 213 6 6 225 6 5 224 6 8
Low-density lipoprotein (mg/dL) 134 6 6 147 6 5 147 6 7
High-density lipoprotein (mg/dL) 42 6 2 44 6 2 42 6 2
Triglycerides (mg/dL) 190 6 15 182 6 19 185 6 16
Hypertension (%) 34 (58) 47 (56) 13 (38)
Diabetes (%) 10 (17) 18 (21) 2 (6)
Coronary atherosclerosis (%) 31 (53) 42 (50) 19 (56)
*p 5 0.001, DD vs. II.
ACE 5 angiotensin-converting enzyme; Hx 5 history; SD 5 standard deviation.
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110 6 1 to 103 6 1 mm Hg (p , 0.001), but the change
was not significantly different between the genotype groups.
There was a progressive decrease in coronary epicardial and
microvascular responses to SNP in the presence of the ACE
D allele, with the lowest response in patients homozygous
for the D allele, intermediate response in those with the
ACE ID genotype and greatest response in those homozy-
gous for the I allele (p , 0.003 for flow and p 5 0.085 for
diameter by ANOVA, Fig. 1). Thus, compared with pa-
tients with the ACE DD genotype, those with ACE II
genotype had greater increase in flow (196 6 26% vs. 121 6
11%, p 5 0.003) and diameter (21.9 6 2% vs. 17 6 1%, p 5
0.03) with SNP. In multivariate analysis, the presence of the
ACE D allele (p 5 0.007) and diabetes mellitus (p 5 0.04)
were independent predictors of the magnitude of increase in
coronary blood flow with SNP.
The responses to SNP in patients with AT1 AA, AC and
CC genotypes were similar (Fig. 2, Table 3). The analysis
for the interaction between the two polymorphisms was
performed in patients with the D allele of the ACE gene.
There was no difference in the responses in individuals with
the ACE D allele (DD or ID) who were homozygous for
the A allele when compared to those possessing the C allele
(AC and CC genotypes) of the AT1 receptor gene (Table
3).
Genotype and coronary vascular response to ACH. Ace-
tylcholine 1026 moles/L infusion did not alter the mean
arterial pressure. Coronary vascular responses to ACH were
similar in patients with the ACE DD, ID and II genotypes
(p . 0.1 for flow and diameter changes, Fig. 1). Because
smooth muscle reactivity differed between subgroups, we
also analyzed the response to ACH as a ratio of the response
Figure 1. Effects of acetylcholine and sodium nitroprusside on coronary
vascular resistance, coronary blood flow and epicardial diameter according
to angiotensin-converting enzyme genotype.
Figure 2. Effects of acetylcholine and sodium nitroprusside on coronary
vascular resistance, coronary blood flow and epicardial diameter according
to angiotensin type I receptor genotype.
Table 2. Baseline Coronary and Systemic Hemodynamics
Study 1 DD ID II
Mean blood pressure (mm Hg) 111 6 2 112 6 2 109 6 3
Epicardial diameter (mm) 2.0 6 0.1 2.0 6 0.1 2.0 6 0.1
Coronary blood flow (ml/min) 46 6 4 47 6 5 47 6 9
Coronary vascular resistance
(mm Hg z ml21 z min)
3.6 6 0.4 3.7 6 0.3 3.9 6 0.5
Study 2
Mean blood pressure (mm Hg) 109 6 2 112 6 3 106 6 3
Epicardial diameter (mm) 1.9 6 0.1 2.0 6 0.1 2.0 6 0.1
Coronary blood flow (ml/min) 45 6 8 60 6 10 46 6 6
Coronary vascular resistance
(mm Hg z ml21 z min)
3.9 6 0.7 3.2 6 0.4 3.4 6 0.5
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to SNP. The ratio of the coronary blood flow increase with
ACH compared with the increase with SNP was 1.1 6 1,
1.0 6 0.1 and 0.9 6 0.1 in the ACE DD, ID and II
genotypes, respectively (p 5 NS, by ANOVA). Similarly,
the ratio of ACH versus SNP responses in the epicardial
coronary arteries were not significantly different.
The responses to ACH were also not different in patients
with the AT1 AA, AC and CC genotypes (Table 3, Fig. 2).
An analysis for the interaction between the two polymor-
phisms, as described for SNP, was also performed for ACH
responses, and no difference was found (Table 3).
Study 2: genotype and coronary vascular response to
L-NMMA. The frequencies of the D and I alleles were
52% and 48%, and the frequencies of the ACE DD, ID and
II genotypes were 29%, 46% and 25%, respectively, in this
subgroup. Genotype frequency did not deviate significantly
from that predicted by the Hardy–Weinberg equilibrium.
Baseline systemic and coronary hemodynamics and the
distribution of conventional risk factors for endothelial
dysfunction were similar in patients with all three genotypes
(Table 2).
L-NG monomethyl arginine infusion increased mean
arterial pressure from 110 6 2 to 117 6 2 mm Hg (p ,
0.001) in the total study population, and the magnitude of
increase was similar in the three genotype subsets. The
increase in coronary vascular resistance and the reduction in
blood flow with L-NMMA was greater in patients with the
ACE D allele (p 5 0.07, by ANOVA for both, Fig. 3).
Thus, the 27 6 3% reduction in coronary blood flow in the
ACE DD patients was higher than the ACE II patients in
whom blood flow changed by 5 6 4%, p 5 0.003. Patients
with the ACE ID genotype had an intermediate response.
In multivariate analysis, the presence of the ACE D allele
(p 5 0.08) appeared to be a predictor of the magnitude of
change in coronary blood flow with L-NMMA.
Although the trend toward a decreased epicardial re-
sponse to L-NMMA in patients with the ACE II genotype
did not reach statistical significance compared with those
with the ACE DD genotype in the whole group (Fig. 3),
this difference was significant in the subgroup of 37 patients
with angiographic atherosclerosis in whom epicardial diam-
eter decreased by 6.3 6 1.2%, 5.0 6 1.4% and 1.9 6 1.2%
in ACE DD, ID and II genotypes, respectively (p 5 0.04,
by ANOVA).
DISCUSSION
To obtain insights into mechanisms underlying the associ-
ation between the D allele and increased prevalence of
vascular disease, we examined the effects of the ACE gene
polymorphism on coronary endothelial and smooth muscle
function. Endothelial function was studied using both
L-NMMA, to estimate basal NO activity, and ACH, to
estimate endothelial function upon pharmacologic stimula-
tion. Smooth muscle function was assessed using an
endothelium-independent dilator, SNP. Our study demon-
strates that the presence of the ACE D allele: a) is
Figure 3. Effects of L-NG monomethyl arginine (L-NMMA) on coronary
vascular resistance, coronary blood flow and epicardial diameter according
to angiotensin-converting enzyme genotype.
Table 3. Coronary Epicardial and Microvascular Responses According to the AT1 Receptor Gene Polymorphism
Variables % Change AA AC CC ANOVA D 1 AA D 1 AC/CC p Value
Sodium nitroprusside
Resistance 253 6 2 258 6 3 251 6 7 0.1 251 6 3 253 6 3 0.5
Flow 130 6 8 164 6 20 139 6 36 0.2 125 6 9 129 6 14 0.6
Diameter 18.7 6 1.1 18.1 6 1.3 17.7 6 2.5 0.9 17.8 6 1.2 17.1 6 1.3 0.7
Acetylcholine
Resistance 241 6 3 249 6 3 241 6 6 0.2 241 6 3 248 6 3 0.2
Flow 107 6 10 146 6 19 104 6 31 0.1 105 6 11 128 6 15 0.1
Diameter 21.0 6 0.8 0.7 6 1.2 23.4 6 2.4 0.2 21.8 6 0.9 1.0 6 1.1 0.5
p value 5 D 1 AA vs. D 1 AC/AC.
ANOVA 5 analysis of variance, AA vs. AC vs. CC; AT1 5 angiotensin type I.
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associated with depressed vasodilation with SNP denoting
increased vascular smooth muscle tone; b) is associated with
enhanced vasoconstriction with L-NMMA confirming in-
creased basal NO activity; and c) does not influence ACH
responses, indicating that the ACE genotype may not be a
determinant of stimulated endothelial function in the cor-
onary circulation of patients with atherosclerosis or one of
its risk factors. Furthermore, the 1,166 A/C AT1 receptor
gene polymorphism does not influence coronary vascular
endothelial or smooth muscle function.
ACE deletion allele and basal constrictor tone. A signif-
icant reduction in the dilator response of microvessels and
epicardial arteries with SNP, a NO donor that directly
stimulates smooth muscle production of cyclic guanylate
monophosphate, was observed in patients with the D allele,
compared with those with the ACE II genotype. This
reduced vasodilation with SNP may reflect enhanced
smooth muscle constrictor tone due to higher angiotensin II
and lower bradykinin activity (25,27,29,30) in blood vessels
of patients with the ACE D allele who have increased
circulating and tissue ACE levels (23,24). In addition, these
patients may also have increased smooth muscle constrictor
tone due to angiotensin II–mediated endothelin release and
stimulation of sympathetic activity (15,16). Since this in-
creased smooth muscle constrictor tone in patients with the
D allele was not associated with increased resting coronary
vascular resistance and smaller epicardial diameters, it is
likely that counter–regulatory endogenous release of dilating
substances, possibly endothelium-derived, is also upregu-
lated in these patients. This possibility is supported by our
observation that basal NO activity was higher in individuals
with the D allele.
D allele and basal NO activity. Presence of the ACE D
allele was associated with greater microvascular and epicar-
dial constriction with L-NMMA compared with those with
the ACE II genotype. This may be a consequence of higher
basal NO activity and/or increased vasoconstrictor tone in
the coronary vasculature of individuals with the ACE D
allele. The former mechanism is supported by a previous in
vitro study in which higher basal NO activity was present in
internal mammary artery segments from patients with CAD
who possessed the ACE D allele (26). Furthermore, this is
analogous to the recent finding that a high lipoprotein(a)
level, another risk factor for cardiovascular disease, is asso-
ciated with increased basal NO release (31). It is important
to recognize that the variable stimulation of basal NO
activity occurred despite the presence of multiple risk factors
that are themselves associated with reduced NO activity
(13). Multivariate analysis of determinants of basal NO
activity (L-NMMA response) demonstrated that the ACE
D allele tended to be an independent determinant of the
L-NMMA response in the coronary microvasculature. This
emphasizes the important additional role of the D genotype
and, hence, tissue ACE activity on NO bioavailability. The
mechanisms underlying this observation may be explained
by the fact that angiotensin II itself stimulates NO release.
Angiotensin II promotes NO release in a dose-dependent
manner by activating NO synthase either via the AT1 or
AT2 receptor stimulation (19,20,22). This raises the possi-
bility that activation of the tissue renin-angiotensin system
in atherosclerosis (32) may also regulate basal NO activity in
humans so that greater angiotensin II activity in individuals
with the ACE D allele would be expected to lead to higher
basal NO release.
Alternatively, it is also likely that the greater response to
L-NMMA may be due to the increased smooth muscle tone
in patients with the D allele, as suggested by the diminished
vasodilator response to SNP as discussed above. The lack of
difference in basal coronary vascular tone in patients with
different ACE I/D genotypes leads us to speculate that the
increased smooth muscle tone is offset by increased produc-
tion of endogenous vasodilators such as NO.
ACE D allele and stimulated endothelial function. En-
dothelial dysfunction is characterized by depressed microvas-
cular and epicardial dilation in response to pharmacologic
probes including ACH (13). In our study ACH-mediated
microvascular and epicardial vasomotion was similar in all three
genotype groups, indicating that the ACE gene polymorphism
does not modulate endothelium-dependent vasomotor dys-
function in patients with one or more risk factors for athero-
sclerosis. Because smooth muscle tone as assessed by SNP, an
NO donor, was increased in patients with the ACE D allele, it
is important to interpret the unchanged response with ACH,
that releases NO via the endothelium, in this population with
caution. We therefore analyzed the response to ACH as a ratio
of the response to SNP and found no statistical difference
between the groups, confirming that stimulated endothelium-
dependent vasomotion was not different between the groups.
An explanation as to why the response to ACH is unaltered
when the response to an endothelium-independent NO donor,
SNP, is reduced in patients with the D allele may be that these
patients had enhanced stimulated NO release. This possibility
is consistent with the observed increase in basal NO activity.
Alternatively, there may be increased release non–NO
endothelium-derived relaxing factors in response to ACH, a
release that compensates for the increased smooth muscle tone
in patients with the ACE D allele.
Our findings are consistent with a previous study in
individuals without risk factors for atherosclerosis in whom
the ACE gene polymorphism also did not determine
endothelial function, which was assessed by brachial artery
dilation during reactive hyperemia (28). However, a recent
study reported that individuals with the ACE DD genotype
had higher plasma PAI-1 levels, von Willebrand factor and
thrombomodulin, all markers of endothelial dysfunction
(33,34). This raises the possibility that the ACE gene
polymorphism may impair functions of the endothelium
that are independent of factors that control vasomotion.
AT1 receptor polymorphism and vasomotor function. In
our study the A/C polymorphism of the angiotensin AT1
receptor gene did not influence endothelial or smooth
muscle function either directly or in synergy with the ACE
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gene. Because of the low frequency of the C allele, we were
unable to determine the influence of this polymorphism on
basal NO activity. Though the polymorphism has been
previously associated with enhanced coronary vasoconstric-
tion with methylergonovine (35), our data suggest that the
receptor polymorphism is not a major determinant of
vasomotor function in patients with atherosclerosis or its
risk factors. This conclusion is consistent with the fact that
the genetic variant is: a) located in the noncoding region and
thus does not alter the amino acid sequence of the receptor
protein, b) not a direct risk factor for coronary artery disease
and c) only a weak risk factor for hypertension (5,36).
Study limitations. Although we did not evaluate the va-
somotor responses to bradykinin here, in a subsequent study
we observed that epicardial dilation with bradykinin is
diminished in individuals with the ACE D allele compared
with those with the II genotype (37). Together with the
present study, these data indicate that the ACE gene
polymorphism modulates kinin but not muscarinic receptor
mediated endothelial function. We did not investigate the
interaction between the presence of the ACE D allele and
individual risk factors for CAD in determining vascular
function, because of the limited and selected population.
We also did not investigate whether the ACE I/D poly-
morphism affected other functions of the endothelium, such
as adhesion molecule expression, lipid oxidation and PAI-1
synthesis, which are all sensitive to angiotensin II. It is
possible that the deleterious effects of the D allele in the
ACE gene and the C allele of the AT1 receptor gene may
be mediated through one or more of these mechanisms.
Conclusions and implications. For the first time, to our
knowledge, we demonstrated the influence of a patient’s
genotype on coronary vasomotor function, which reveals the
complex inter-relationships between vasoconstrictors and
vasodilators and activation of compensatory pathways. We
show that in patients with either atherosclerosis or its risk
factors, the D allele of the ACE gene is associated with
greater basal NO activity, possibly in compensation for the
increased vascular smooth muscle tone, which may be
secondary to increased local angiotensin II and reduced
bradykinin activities. Thus, the ACE I/D polymorphism
may predispose to hypertension, MI and coronary artery
spasm (37) (ref. 37 published in this issue of the Journal),
not by inducing endothelial injury but by promoting smooth
muscle vasoconstriction. This conclusion is supported by the
recent observation that individuals with the ACE DD
genotype have greater systemic constrictor response to
phenylepherine and increased angiotensin II–induced po-
tentiation of phenylepherine-mediated constriction of arte-
rial segments in vitro compared with those with the ACE
ID/II genotypes (39). Finally, the AT1 receptor A/C
polymorphism is not a determinant of coronary vasomotor
function and does not modulate the effects of the ACE
genotype on the vascular phenotype.
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